147 related articles for article (PubMed ID: 37548456)
21. Clinical characteristics and risk factors of tigecycline-associated hypofibrinogenaemia in critically ill patients.
Hu J; Xiao YH; Zheng Y; Lai YX; Fang XL; Fang Q
Eur J Clin Pharmacol; 2020 Jul; 76(7):913-922. PubMed ID: 32355990
[TBL] [Abstract][Full Text] [Related]
22. A case report of tigecycline induced acute pancreatitis in a renal transplant patient and review of the literature: Should we avoid tigecycline in patients on calcineurin inhibitors?
Yazirli B; Kara E; Inkaya AC; Maden S; Ozberk U; Yildirim T; Parlak E; Uzun O; Yilmaz SR; Arici M
Transpl Infect Dis; 2021 Aug; 23(4):e13593. PubMed ID: 33655683
[TBL] [Abstract][Full Text] [Related]
23. Tigecycline-Associated Acute Pancreatitis.
Akhter S; Krishnan P; Kaul P
Am J Ther; 2018; 25(6):e749-e750. PubMed ID: 29672331
[No Abstract] [Full Text] [Related]
24. Acute pancreatitis related to tigecycline: case report and review of the literature.
Gilson M; Moachon L; Jeanne L; Dumaine V; Eyrolle L; Morand P; Ben m'Rad M; Salmon D
Scand J Infect Dis; 2008; 40(8):681-3. PubMed ID: 18979610
[TBL] [Abstract][Full Text] [Related]
25. Early experience with tigecycline for ventilator-associated pneumonia and bacteremia caused by multidrug-resistant Acinetobacter baumannii.
Schafer JJ; Goff DA; Stevenson KB; Mangino JE
Pharmacotherapy; 2007 Jul; 27(7):980-7. PubMed ID: 17594203
[TBL] [Abstract][Full Text] [Related]
26. Successful treatment of postoperative multidrug-resistant Acinetobacter baumannii meningitis by tigecycline.
Kooli I; Brahim HB; Kilani M; Gannouni C; Aouam A; Toumi A; Loussaief C; Hattab MN; Chakroun M
J Glob Antimicrob Resist; 2016 Jun; 5():62-3. PubMed ID: 27436468
[TBL] [Abstract][Full Text] [Related]
27. Prolonged and high dosage of tigecycline - successful treatment of spondylodiscitis caused by multidrug-resistant Acinetobacter baumannii: a case report.
Tsachouridou O; Georgiou A; Nanoudis S; Chrysanthidis T; Loli G; Morfesis P; Zebekakis P; Metallidis S
J Med Case Rep; 2017 Jul; 11(1):186. PubMed ID: 28687078
[TBL] [Abstract][Full Text] [Related]
28. Serum concentration as a predictor of tigecycline-induced hypofibrinogenemia in critically ill patients: A retrospective cohort study.
Yang X; Jin L; Luo X; Wang M; Zhu H; Zhou Y; Ge W
Int J Infect Dis; 2022 Oct; 123():136-142. PubMed ID: 36028209
[TBL] [Abstract][Full Text] [Related]
29. Successful treatment of septic shock due to pan-resistant Acinetobacter baumannii using combined antimicrobial therapy including tigecycline.
Taccone FS; Rodriguez-Villalobos H; De Backer D; De Moor V; Deviere J; Vincent JL; Jacobs F
Eur J Clin Microbiol Infect Dis; 2006 Apr; 25(4):257-60. PubMed ID: 16572310
[TBL] [Abstract][Full Text] [Related]
30. Acute necrotizing pancreatitis: can tigecycline be included in a therapeutic strategy?
Occhionorelli S; Morganti L; Cultrera R; Andreotti D; Maccatrozzo S; Cappellari L; Stano R; Vasquez G
G Chir; 2015; 36(1):15-20. PubMed ID: 25827664
[TBL] [Abstract][Full Text] [Related]
31. Tigecycline-related pancreatitis: a review of spontaneous adverse event reports.
Okon E; Engell C; van Manen R; Brown J
Pharmacotherapy; 2013 Jan; 33(1):63-8. PubMed ID: 23307547
[TBL] [Abstract][Full Text] [Related]
32. A Phase 3, open-label, non-comparative study of tigecycline in the treatment of patients with selected serious infections due to resistant Gram-negative organisms including Enterobacter species, Acinetobacter baumannii and Klebsiella pneumoniae.
Vasilev K; Reshedko G; Orasan R; Sanchez M; Teras J; Babinchak T; Dukart G; Cooper A; Dartois N; Gandjini H; Orrico R; Ellis-Grosse E;
J Antimicrob Chemother; 2008 Sep; 62 Suppl 1():i29-40. PubMed ID: 18684704
[TBL] [Abstract][Full Text] [Related]
33. Severe coagulation disorder with hypofibrinogenemia associated with the use of tigecycline.
Pieringer H; Schmekal B; Biesenbach G; Pohanka E
Ann Hematol; 2010 Oct; 89(10):1063-4. PubMed ID: 20174923
[No Abstract] [Full Text] [Related]
34. Acinetobacter baumannii bloodstream infection while receiving tigecycline: a cautionary report.
Peleg AY; Potoski BA; Rea R; Adams J; Sethi J; Capitano B; Husain S; Kwak EJ; Bhat SV; Paterson DL
J Antimicrob Chemother; 2007 Jan; 59(1):128-31. PubMed ID: 17082201
[TBL] [Abstract][Full Text] [Related]
35. Acute liver failure caused by high-dose tigecycline: A case report.
Zhang Y; Wang J; Tan Y; Wu J
Int J Clin Pharmacol Ther; 2024 Jul; 62(7):339-344. PubMed ID: 38606856
[TBL] [Abstract][Full Text] [Related]
36. Spinal arachnoiditis followed by intrathecal tigecycline therapy for central nervous system infection by extremely drug-resistant
Li LM; Zheng WJ; Shi SW
J Int Med Res; 2020 Jul; 48(7):300060520920405. PubMed ID: 32628870
[TBL] [Abstract][Full Text] [Related]
37. A case report of intraventricular tigecycline therapy for intracranial infection with extremely drug resistant Acinetobacter baumannii.
Fang YQ; Zhan RC; Jia W; Zhang BQ; Wang JJ
Medicine (Baltimore); 2017 Aug; 96(31):e7703. PubMed ID: 28767605
[TBL] [Abstract][Full Text] [Related]
38. Risk Factors for Tigecycline-Associated Hypofibrinogenemia.
Liu J; Yan Y; Zhang F
Ther Clin Risk Manag; 2021; 17():325-332. PubMed ID: 33888987
[TBL] [Abstract][Full Text] [Related]
39. Rapid development of Acinetobacter baumannii resistance to tigecycline.
Reid GE; Grim SA; Aldeza CA; Janda WM; Clark NM
Pharmacotherapy; 2007 Aug; 27(8):1198-201. PubMed ID: 17655518
[TBL] [Abstract][Full Text] [Related]
40. Efficacy of tigecycline/colistin combination in a pneumonia model caused by extensively drug-resistant Acinetobacter baumannii.
Mutlu Yilmaz E; Sunbul M; Aksoy A; Yilmaz H; Guney AK; Guvenc T
Int J Antimicrob Agents; 2012 Oct; 40(4):332-6. PubMed ID: 22831842
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
